MAPT and Alzheimer disease: Plasma biomarkers have the potential to democratize Alzheimer’s disease (AD) diagnosis, with accumulating evidence of high accuracy to detect AD pathology and strong correlations with β-amyloid (Aβ) and tau pathologies1–5.